louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01254435: Positioning During Colonoscopy
Official title: Does Patient Position During Extubation at Colonoscopy Influence the Quality of Mucosal Visualisation?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Colonic Polyps
Keywords: Colonoscopy
Positioning in colonoscopy
Quality control
Lead sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Sponsor class: OTHER
First posted: 2010-12-06
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Colonoscopy is the gold standard investigation in the screening of colorectal neoplasms. The investigators hypothesise that visualisation of the colonic mucosa on extubation may be improved by changing patient position as follows: left lateral position for the right colon, supine for the transverse colon and right lateral position for the left colon(fixed positioning). The investigators aim to validate our hypothesis by performing a randomised control study, comparing mucosal visualisation in patients placed in the 'routine' positions at the discretion of the endoscopist with visualisation in those placed in the above described positions. The hypothesis is that fixed positioning confers an advantage.


Eligibility criteria: Inclusion Criteria:

* Patients requiring colonoscopy

Exclusion Criteria:

* Polyp surveillance
* Cancer surveillance
* Infirmity
* Pregnancy
* Colectomy
* Poor tolerance
* Failed colonoscopy
* Poor bowel preparation

Primary outcomes:
measure: Mucosal visualisation
timeFrame: 3 months
measure: Luminal distension
Secondary outcomes:
Other outcomes:
Locations:
city: Sheffield
country: United Kingdom
facility: Sheffield Teaching Hospitals NHS Trust
state: South Yorkshire
Study officials:
affiliation: Sheffield Teaching Hospitals NHS Foundation Trust
name: Steven R Brown, MD FRCS
role: PRINCIPAL_INVESTIGATOR
affiliation: Sheffield Teaching Hospitals NHS Foundation Trust
name: Stuart Riley, FRCP
role: STUDY_DIRECTOR
affiliation: University of Sheffield
name: Wal Baraza, MRCS
role: STUDY_CHAIR
References:
Clinical trial NCT02484235: Effects of High Intensity Interval Training and Strength Training in Obese
Official title: Effects of High Intensity Interval Training, Strength Training and the Combination in Overweight and Obese
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Obesity
Keywords: obesity
exercise
HIIT
Vo2
kinetics
Lead sponsor: University of Chile
Sponsor class: OTHER
First posted: 2015-06-29
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Obesity is a global health problem since it is associated with many cardiovascular and metabolic diseases, osteoarticular problems and some cancers. That is why it is a priority of the national health policies. Exercise is a mainstay in the treatment, but still the most effective method is sought. The resistance exercise and high intensity intervals (HIIT) have been shown to positively affect the outcome of the disease, increasing the oxidative capacity of the trained subjects. Therefore it is important to look if both together produce greater benefits or otherwise nullify its effects, such as suggested by recent publications in relation to the cellular response to different stimuli such exercise in skeletal muscle. The aim of this study is to evaluate the effectiveness of interventions exercise high intensity intervals, overload and combining them in the oxidative capacity of obese subjects.


Eligibility criteria: Inclusion Criteria:

* Indication of medical supervised exercise
* BMI of 25-35kg/m2
* Participate in a 10 session rehabilitation program

Exclusion Criteria:

* Osteomuscular injuries
* Cardiovascular disease without control
* Bariatric Surgery
* High blood pressure without control

Primary outcomes:
measure: Exercise Test of Vo2 kinetics
timeFrame: 6 weeks
Secondary outcomes:
measure: Strength test of 10 maximum repetition (10RM)
timeFrame: 6 weeks
measure: Exercise test of max Walking Speed
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Hospital Clinico de la Universidad de Chile
state: Metropolitana
Study officials:
References:
Clinical trial NCT05415735: Stress Management and Resiliency Training Following Acute Myocardial Infarction
Official title: Total-Body PET Imaging to Understand the Physiology of Stress, Inflammation, and Meditation Following a Heart Attack
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Attack
Cardiovascular Diseases
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2022-06-13
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The goal of this pilot study is to use total body PET/CT imaging to examine the relationships between stress, amygdala activation, and arterial wall inflammation in participants before and after participating in a multi-modal stress reduction program.


Eligibility criteria: Inclusion Criteria:

* Concurrently enrolled in an observational study of patients who have had an acute myocardial infarction
* Score on PSS-10 of 14 or greater during screening
* Willing and able to access the internet to participate in the online SMART Program

Exclusion Criteria:

* Poorly controlled physical or mental health condition that would likely interfere with the ability to participate in SMART or ability to undergo PET scan
* Current daily practice of meditation of 10 minutes or more per day

Primary outcomes:
measure: Change in amygdala activation
timeFrame: about 10 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis
state: California
Study officials:
References:
Clinical trial NCT06977035: Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib
Official title: Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Rheumatoid Arthritis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2025-05-16
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues. Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA). Nerve conduction studies (NCSs) are an essential tool in the evaluation of the peripheral nervous system. The sensory nerve action potential (SNAP) provides information on the sensory nerve axon and its pathway from the distal receptors in the skin to the dorsal root ganglia, while the compound muscle action potential (CMAP) is an assessment of the motor nerve fibers from their origins in the anterior horn cell to their termination along muscle fibers.


Eligibility criteria: Inclusion Criteria:

1. Patients fulfill the 2010 ACR/EULAR classification criteria of RA
2. Age above 18 years old.
3. Patient cooperative and can answer questions

Exclusion Criteria:

1. Other rheumatologic or collagen diseases.
2. Age below 18 years and above 65 years.
3. Uncooperative patients.
4. Patients with other causes of peripheral neuropathy as Diabetes mellitus.

Primary outcomes:
measure: prevalence of Peripheral Neuropathy in Rheumatoid Arthritis Patients on Baricitinib
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023 Nov 25;402(10416):2019-2033. doi: 10.1016/S0140-6736(23)01525-8. Epub 2023 Oct 27.
citation: Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998 May;27 Suppl 1:S18-24. doi: 10.1016/s0720-048x(98)00038-2.
citation: Al-Salama ZT, Scott LJ. Baricitinib: A Review in Rheumatoid Arthritis. Drugs. 2018 May;78(7):761-772. doi: 10.1007/s40265-018-0908-4.
citation: Mallik A, Weir AI. Nerve conduction studies: essentials and pitfalls in practice. J Neurol Neurosurg Psychiatry. 2005 Jun;76 Suppl 2(Suppl 2):ii23-31. doi: 10.1136/jnnp.2005.069138. No abstract available.
Clinical trial NCT00408135: Japanese Study Evaluating Safety, Efficacy and Acceptability of Telithromycin in Children With Infections
Official title: Evaluation of the Safety, Efficacy and Acceptability of HMR 3647 (20％ Fine Granules 1 g Sachet) in Children With Infections
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Infections
Child
Keywords: Respiratory Tract Infections
Skin Diseases
Sinusitis
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2006-12-06
Enrollment: 111
Sex: ALL
Minimum age (years): 6
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective is to assess the safety of telithromycin (HMR 3647) (20% fine granules) 1g filling sachet in children with infections (Respiratory tract infections, Dermatological infections, Otorhinolaryngological infections, Dentistry/Oral surgery infections).

Secondary objectives are to assess the clinical efficacy, bacteriological efficacy and acceptability of telithromycin (20% fine granules) 1g filling sachet in children with infections.


Eligibility criteria: Inclusion Criteria:

* Outpatients of weight from 7.0 kg.
* For respiratory tract infections:subjects diagnosed with mild or moderate respiratory tract infection (excluding pneumonia) based on a fever (≥ 38°C) or C-Reactive Protein positive, clinical symptoms/signs, and laboratory findings.
* For dermatological infections: subjects diagnosed with mild or moderate dermatological infection in terms of clinical symptoms/signs and laboratory findings.
* For otorhinolaryngological infections:subjects with purulent / mucopurulent rhinorrhea and postrhinorrhea, subjects diagnosed with mild or moderate otorhinolaryngological infection in terms of clinical symptoms/signs and laboratory findings
* For dental / oral surgical infections: subjects who have formed obstructive abscess and diagnosed with mild or moderate dental / oral surgical infection

Primary outcomes:
measure: Safety evaluation: presence/absence of subjective/objective symptoms and abnormal laboratory findings (abnormal changes of parameters in general hematological tests and blood biochemical tests).
Secondary outcomes:
measure: Clinical efficacy:change in the symptoms and signs at end of therapy visit and at the test of cure visit
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Sanofi-Aventis
Study officials:
affiliation: sanofi-aventis Japan
name: Norifumi Yamamoto
role: STUDY_DIRECTOR
References:
Clinical trial NCT01917435: Video-stylet for Nasotracheal Intubation in Limited Mouth Opening Patient
Official title: Nasotracheal Intubation Assisted by a Video-stylet in Limited Mouth Opening Patient
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Anesthesia Intubation Complication
Keywords: fiberoptic bronchoscopy,
Video-stylet,
Nasotracheal Intubation
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2013-08-06
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to investigate the efficiency of the Video-stylet (Trachway ®) and the fiberoptic bronchoscopy in facilitation of nasotracheal intubation in limited mouth opening patients.


Eligibility criteria: Inclusion Criteria:

1. patients with American Society of Anesthesiologists physical status I-III
2. aged 20-65 years
3. Requiring Nasotracheal Intubation under general anesthesia
4. limited mouth open ,mouth open \< 3 cm
5. unlimited neck motion

Exclusion Criteria:

1. Ankylosing arthritis patients.
2. BMI≧35 kg/m2

Primary outcomes:
measure: number of the patients with successful nasotracheal intubation and scoring modified intubation difficulty scale
timeFrame: half an hour
Secondary outcomes:
measure: time to intubate
timeFrame: half an hour
Other outcomes:
measure: perioperative epistaxis, sore throat and hoarseness
timeFrame: 2 days
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung-Ho Memorial Hospital
Study officials:
References:
Clinical trial NCT05488535: Non-significant Risk Study of a Cochlear Implant Headpiece
Official title: Non-significant Risk Study of a Cochlear Implant Headpiece
Study type: INTERVENTIONAL
Overall status: COMPLETED
Conditions: Hearing Loss
Sensorineural Hearing Loss
Keywords: cochlear implant
Lead sponsor: Advanced Bionics
Sponsor class: INDUSTRY
First posted: 2022-08-04
Enrollment: 101
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate a cochlear implant headpiece.

Detailed description: The headpiece and magnet are expected to provide acceptable comfort and retention for existing cochlear implant users. In this study participants will report on their experience with the investigational headpiece during daily life.

Eligibility criteria: Inclusion Criteria:

* Pre- or post-lingually deafened.
* Fluent in English, French, or Spanish or capable of communication with a caregiver who is providing consent.
* Adult or child implanted with a commercially available Advanced Bionics cochlear implant. Children and adult participants are included to ensure device retention is appropriate for all implant populations.
* Have (or caregivers have) the cognitive and functional capability to comply with all directions during the study
* Be able to remove their own headpiece
* Have (or caregivers have) the cognitive and functional capability to complete the questionnaire required for the study
* Capable (or caregivers are capable) of reading and understanding patient information materials and giving written informed consent

Exclusion Criteria:

* Have any significant medical condition that, in the opinion of any of the investigators, is likely to interfere with study procedures or likely to confound evaluation of study data.

Primary outcomes:
measure: Subjective Report of Headpiece Comfort and Retention
timeFrame: Assessed every two months from month 2 to month 12, values at study close out (month 12) reported.
Secondary outcomes:
Other outcomes:
Locations:
city: Valencia
country: United States
facility: Advanced Bionics
state: California
Study officials:
References:
Clinical trial NCT02694835: Initial Performance of a Modified Daily Disposable Contact Lens
Official title: Initial Performance of a Modified Daily Disposable Silicone Hydrogel Contact Lens
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Refractive Error
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2016-03-01
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to evaluate the incidence of ocular discomfort device-related adverse events with DAILIES TOTAL1® with UV Absorber (DT1 UV) contact lenses compared with current DAILIES TOTAL1® (DT1) contact lenses.


Eligibility criteria: Inclusion Criteria:

* Must sign an Informed Consent document;
* Current wearers of commercial DT1 lenses (for at least 3 months), with a minimum wearing time of 5 days per week and 8 hours per day;
* Spherical contact lens correction within the range of -2.00 to -4.00 Diopter (D) in both eyes;
* Manifest astigmatism less than or equal to 0.75 D (at screening);
* Best-corrected visual acuity (BCVA) greater than or equal to 20/25 in each eye (as determined by manifest refraction at screening);
* Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

* Eye injury in either eye within 12 weeks prior to study enrollment;
* Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear as determined by the Investigator;
* Use of systemic or ocular medications for which contact lens wear could be contraindicated, including topical ocular medications and lubrication drops that would require instillation during contact lens wear;
* History of herpetic keratitis;
* History of refractive surgery or irregular cornea;
* Pathologically dry eye that precludes contact lens wear;
* Concurrent participation (or within the previous 30 days) in a contact lens or lens care product clinical trial;
* Monocular (only 1 eye with functional vision);
* Other protocol-specified exclusion criteria may apply.

Primary outcomes:
measure: Incidence (Number) of Ocular Discomfort Device-related Adverse Events (AEs)
timeFrame: Day 1 at Hour 9 ± 3 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Alcon Research
name: Clinical Manager, GCRA
role: STUDY_DIRECTOR
References:
Clinical trial NCT01572558: Conservative Treatment of Acute Appendicitis in Children
Official title: Conservative Treatment of Acute Appendicitis in Children Pilot Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Appendicitis
Child
Keywords: Appendectomy
Nonsurgical treatment with antibiotics
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
First posted: 2012-04-06
Enrollment: 51
Sex: ALL
Minimum age (years): 5
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a feasibility study that will be performed at the Astrid Lindgren Children´s Hospital, Karolinska University Hospital, Stockholm, Sweden. It will involve 50 patients, randomized to either conservative, non-operative, treatment with antibiotics OR surgery. The study will test an computerized randomization system, the availability of patients willing to participate in the trial and the trial protocol. The investigators will assess the characteristics of the patients who agree to participate in the study and those who do not. The investigators will explore short term outcome and design suitable long term outcome measures.


Eligibility criteria: Inclusion Criteria:

* Children 5-15 years old with a clinical diagnosis of appendicitis that prior to the trial would have been subjected to a surgical intervention

Exclusion Criteria:

* Suspicion of perforated appendicitis on the basis of generalized peritonitis
* An appendiceal mass, diagnosed either by palpation or with radiology

Primary outcomes:
measure: Resolution of symptoms without significant complications
timeFrame: 30 days
Secondary outcomes:
measure: Time in hospital
timeFrame: 7 days
measure: Time to resolution of symptoms
timeFrame: 7 days
measure: Abscess formation
timeFrame: 7 days
measure: Early complications
timeFrame: 7 days
measure: Pain
timeFrame: 48 hours
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Astrid Lindgren Children´s Hospital
Study officials:
affiliation: Karolinska Institutet
name: Jan F Svensson, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Patkova B, Svenningsson A, Almstrom M, Eaton S, Wester T, Svensson JF. Nonoperative Treatment Versus Appendectomy for Acute Nonperforated Appendicitis in Children: Five-year Follow Up of a Randomized Controlled Pilot Trial. Ann Surg. 2020 Jun;271(6):1030-1035. doi: 10.1097/SLA.0000000000003646.
citation: Svensson JF, Patkova B, Almstrom M, Naji H, Hall NJ, Eaton S, Pierro A, Wester T. Nonoperative treatment with antibiotics versus surgery for acute nonperforated appendicitis in children: a pilot randomized controlled trial. Ann Surg. 2015 Jan;261(1):67-71. doi: 10.1097/SLA.0000000000000835.
Clinical trial NCT06855758: Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation
Official title: Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation, a Double-blind Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Kidney Transplant
Delayed Graft Function
Intraoperative Hypotension
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2025-03-04
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Prospective double blind randomized controlled trial. By randomizing patients undergoing kidney transplantation into a conventional catecholamine drug (dobutamine) blood pressure maintenance group and a terlipressin-complexed dobutamine group, the investigators compared the effect of intraoperative blood pressure maintenance and the dosage of the vasoactive drug, postoperative graft function, delayed graft function, and other related complications between the two groups, in order to demonstrate whether the use of terlipressin for blood pressure regulation during kidney transplantation is superior to the existing treatments.


Eligibility criteria: Inclusion Criteria:

* Patients with end-stage renal disease aged 18 years or above

Exclusion Criteria:

* simultaneous multiple organ transplantation
* known allergy to study medication
* known pregnancy status
* cancellation of surgery due to grafts or personal reasons
* persistent severe preoperative hypertension that may not require intraoperative supportive therapy with vasoactive medications
* any other reason that the supervising physician or the anesthesiologist on duty think the patient is not suitable for the study

Primary outcomes:
measure: Delayed graft function
timeFrame: within the first 7 days after op
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Friendship Hospital
Study officials:
affiliation: Department of Anesthesiology, Beijing Friendship Hospital
name: Fushan Xue
role: PRINCIPAL_INVESTIGATOR
References: